One recent study focused on studying the effects of SGLT-2 inhibitors on patients with diabetes with MASLD and hepatic fibrosis using the Fibrosis-4 index, revealing a significant reduction in hepatic fibrosis following 12 months of treatment with SGLT-2 inhibitors in patients with a high baseline Fibrosis-4 index. This evidence concerns the gene SLC5A2 and Hepatic fibrosis.